Advances in oncology care: Targeted therapies

AACN Advanced Critical Care

Volumn 22, Issue 4, 2011, Pages 323-334

  Beatty, Kristi ^a   Winkelman, Christine ^b   Bokar, Joseph A ^a   Mazanec, Polly ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

biology; cancer; chemotherapy; oncology; radiation; targeted therapy

Indexed keywords

EID: 81255150078     PISSN: 15597768     EISSN: 15597776     Source Type: Journal    
DOI: 10.1097/NCI.0b013e3182310178     Document Type: Article

References (26)

1. Hill QA. Intensify, resuscitate or palliate: Decision making in the critically ill patient with haematological malignancy. Blood Rev. 2010;24(1):17-25.
2. Thakkar SG, Fu AZ, Sweetenham JW, et al. Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer. 2008;112(10): 2233-2240.
3. Toffart AC, Minet C, Raynard B, et al. Use of intensive care in patients with nonresectable lung cancer. Chest. 2011;139(1):101-108.
4. McGrath S, Chatterjee F, Whiteley C, Ostermann M. ICU and 6-month outcome of oncology patients in the intensive care unit. QJM. 2010;103(6):397-403.
5. Maschmeyer G, Bertschat FL, Moesta KT, et al. Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur J Cancer. 2003;39(6):783-792.
6. Christodoulou C, Rizos M, Galani E, Rellos K, Skarlos DV, Michalopoulos A. Performance status (PS): A simple predictor of short-term outcome of cancer patients with solid tumors admitted to the intensive care unit (ICU). Anticancer Res. 2007;27(4C):2945-2948.
7. den Boer S, de Keizer NF, de Jonge E. Performance of prognostic models in critically ill cancer patients-a review. Crit Care. 2005;9(4):R458-R463.
8. von Bergwelt-Baildon M, Hallek MJ, Shimabukuro- Vornhagen AA, Kochanek M. CCC meets ICU: Redefining the role of critical care of cancer patients. BMC Cancer. 2010;10:612.
9. Karamlou K, Nichols DJ, Nichols CR. Intensive care unit outcomes in elderly cancer patients. Crit Care Clin. 2003;19(4):657-675.
10. Kaplow R. Special nursing considerations. Crit Care Clin. 2001;17(3):769-789.
11. National Cancer Institute, National Institute of Health. Defining Cancer. http://www.cancer.gov/cancertopics/ cancerlibrary/what-is-cancer. Accessed
12. Mukherjee S. The Emperor of All Maladies: A Biography of Cancer. New York, NY: Simon & Schuster; 2010.
13. Biedrzycki BA. Decision making for cancer clinical trial participation: A systematic review. Oncol Nurs Forum. 2010;37(6):E387-E399.
14. McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. Maryland Heights, St Louis, MO: Mosby Elsevier; 2010.
15. Gerber DE. Targeted therapies: A new generation of cancer treatments. Am Fam Physician. 2008; 77(3):311-319.
16. Wujcik D. Targeted therapy. In: Yarbro CH, Wujcik D, Gobel BH, eds. Cancer Nursing: Principles and Practice. 7th ed. Sudbury, MA: Jones & Bartlett 2011 561-583.
17. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target? Oncologist. 2010;15:130-141.
18. Chibaudel B, Tournigand C, Andre T, et al. Targeted therapies as adjuvant treatment for early stage-colorectal cancer: First impressions and clinical questions. Clin Colorect Cancer. 2010;9(5):269-273.
19. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs. 2008;12:627-638.
20. Perez E. Cardiac toxicity of ErbB2-targeted therapies: What do we know? Clin Breast Cancer Suppl. 2008;(8 suppl):S114-S120.
21. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients; a meta-analysis. Oncology. 2010;79:27-38.
22. Gobel BH. Nursing considerations of bevacizumab use. Oncol Nurs Forum. 2007;12:356-361.
23. Kurtin SE. Targeting the epidermal growth factor receptor in colorectal carcinoma. Cancer Nurs. 2007;30:51-59.
24. Esper P, Gale D, Muehlbauer P. What kind of rash is it: Deciphering the dermatologic toxicities of biologic and targeted agents. Clin J Onc Nurs. 2007;11(5).
25. Wilkes GM, Barton-Burke M. 2011 Oncology Nursing Drug Handbook, Sudbury, MA: Jones & Bartlett.
26. Siena S, Sartore-Bianchi A, Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101(19):1308-1324.